Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 6 Compare versions History 16 Sponsors

Apr 1, 2025 · Senate

Second Reading referred to Health and Human Services Committee then to Appropriations Committee

Mar 4, 2025 · House

Engrossed, signed, to Senate

Mar 4, 2025 · Senate

First Reading

Mar 3, 2025 · House

General Order

Mar 3, 2025 · House

Coauthored by Representative(s) Fugate

Mar 3, 2025 · House

Amended

Mar 3, 2025 · House

Title stricken

Mar 3, 2025 · House

Third Reading, Measure passed: Ayes: 90 Nays: 7

Mar 3, 2025 · House

Referred for engrossment

Feb 26, 2025 · House

CR; Do Pass, amended by committee substitute Health and Human Services Oversight Committee

Feb 5, 2025 · House

Policy recommendation to the Health and Human Services Oversight committee; Do Pass Public Health

Feb 5, 2025 · House

Authored by Senator Rosino (principal Senate author)

Feb 4, 2025 · House

Second Reading referred to Health and Human Services Oversight

Feb 4, 2025 · House

Referred to Public Health

Feb 3, 2025 · House

Authored by Representative West (Josh)

Feb 3, 2025 · House

First Reading

PASSAGE PROBABILITY

24.8% Unlikely

Why this number

Stage base Passed First Chamber — base rate 45%, measured from OK's completed sessions
Momentum +2 60/100 from the pace of recorded action
Time since last action -22 560 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.